ARTICLE | Company News
Artificial intelligence company Ex Scientia Ltd. (Dundee, U.K.) partnered with Sanofi (Euronext:SAN; NYSE:SNY) to design and develop bispecific small molecules to treat metabolic diseases. Ex Scientia declined to disclose specific indications or targets covered by the partnership.
The biotech said it will use its platform to evaluate combinations of drug targets in diabetes that work synergistically, and prioritize target pairs with bispecific binding potential. ...